Mügge A, Heublein B, Kuhn M, Nolte C, Haverich A, Warnecke J, Forssmann W G, Lichtlen P R
Division of Cardiology, Hannover Medical School, Germany.
J Am Coll Cardiol. 1993 Jan;21(1):163-70. doi: 10.1016/0735-1097(93)90732-g.
Because pathologic mechanisms for transplant vasculopathy are still uncertain, we tested the hypothesis that endothelial function, in terms of the release of endothelium-derived relaxing factor (EDRF), is impaired in patients with evidence of angiographic transplant vasculopathy.
The long-term prognosis after heart transplantation is mainly determined by the development of transplant vasculopathy.
The study included 23 patients undergoing diagnostic cardiac catheterization approximately 40 months after heart transplantation. Patients were classified into those with (n = 8) and those without (n = 15) angiographic evidence of transplant vasculopathy. Coronary flow velocity (by intravascular Doppler echocardiography) and epicardial coronary diameter (by quantitative angiography) were determined after intracoronary bolus injections (1 ml) of the endothelium-dependent dilator substance P (20 pmol) and the endothelium-independent dilators nitroglycerin (0.1 mg) and papaverine (8 mg). Substances were injected through the lumen of the Doppler catheter, which was placed into the midportion of the left anterior descending artery.
Increases in blood flow velocity in response to substance P were significantly less in patients with than in patients without evidence of transplant vasculopathy. In addition, flow-mediated dilation of epicardial coronary arteries in response to papaverine was abolished in patients with such evidence. Vasodilation of epicardial coronary arteries in response to nitroglycerin and increases in flow velocity in response to papaverine were similar in both groups.
These results suggest that transplant vasculopathy in heart transplant patients is associated with endothelial dysfunction (that is, impaired EDRF-mediated vasodilation). Furthermore, responsiveness of epicardial arteries to increased flow appears to be abolished in patients with evidence of transplant vasculopathy. These abnormal vascular functions may contribute to the pathogenesis of transplant vasculopathy and its vascular complications.
由于移植血管病的病理机制仍不明确,我们检验了以下假设:在有血管造影显示移植血管病证据的患者中,就内皮衍生舒张因子(EDRF)释放而言,内皮功能受损。
心脏移植后的长期预后主要由移植血管病的发展决定。
该研究纳入了23例心脏移植后约40个月接受诊断性心导管检查的患者。患者被分为有(n = 8)和无(n = 15)移植血管病血管造影证据两组。在冠状动脉内推注(1 ml)内皮依赖性舒张剂P物质(20 pmol)以及非内皮依赖性舒张剂硝酸甘油(0.1 mg)和罂粟碱(8 mg)后,通过血管内多普勒超声心动图测定冠状动脉血流速度,通过定量血管造影测定心外膜冠状动脉直径。这些物质通过置于左前降支动脉中部的多普勒导管管腔注入。
有移植血管病证据的患者对P物质的血流速度增加显著低于无该证据的患者。此外,有该证据的患者对罂粟碱的心外膜冠状动脉血流介导的扩张消失。两组对硝酸甘油的心外膜冠状动脉扩张以及对罂粟碱的血流速度增加相似。
这些结果表明,心脏移植患者的移植血管病与内皮功能障碍(即EDRF介导的血管舒张受损)相关。此外,有移植血管病证据的患者心外膜动脉对血流增加的反应性似乎消失。这些异常的血管功能可能有助于移植血管病及其血管并发症的发病机制。